Capricor, Centene Investors Pursue Class Actions Over Alleged Securities Fraud

Several law firms have issued class action lawsuits and investor alerts concerning alleged securities fraud related to Centene Corporation and Capricor Therapeutics, Inc. Centene faces allegations of issuing misleading statements about its enrollment and morbidity rates, leading to a significant stock price drop after it withdrew its 2025 guidance. Capricor is accused of disseminating false or misleading information about the safety and efficacy of its lead cell therapy drug deramiocel for treating Duchenne muscular dystrophy cardiomyopathy, particularly regarding FDA approval prospects. The FDA denied Capricor’s Biologics License Application, citing insufficient evidence of effectiveness and other regulatory issues, causing the stock to plummet. Multiple firms, including The Gross Law Firm, Pomerantz LLP, and The Portnoy Law Firm, are inviting investors who purchased shares during specified periods to join lawsuits or seek lead plaintiff status before deadlines in September 2025. These actions highlight ongoing investor concerns over corporate disclosures and regulatory challenges in the healthcare and biotech sectors.